The Chairman of MediPharm Labs (Other OTC: MEDIF) is Selling Shares

By Carrie Williams

Today, the Chairman of MediPharm Labs (MEDIFResearch Report), Pat Mccutcheon, sold shares of MEDIF for $480.9K.

See today’s analyst top recommended stocks >>

The company has a one-year high of $1.37 and a one-year low of $0.32.

Based on 4 analyst ratings, the analyst consensus is Moderate Buy with an average price target of $0.56, reflecting a -30.0% downside.

In the last 30 days, insiders have sold $480.9K worth of MEDIF shares and purchased $336.4K worth of MEDIF shares.

Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

MediPharm Labs Corp has the distinction of being the first company in Canada to become a licensed producer for cannabis oil production under the Access to Cannabis for Medical Purposes Regulation without first receiving a cannabis cultivation license. The focus on cannabis concentrates from current Good Manufacturing Practices and ISO standard clean rooms and critical environments laboratory, allows MediPharm Labs to produce purified, pharmaceutical-grade cannabis oil and concentrates for derivative products. The company has invested in research-driven team, technology, downstream extraction methodologies and purpose-built facilities to deliver safe and precisely-dosed cannabis products to patients and consumers.